Maricann’s First Shipment of Product to Germany Opens Door to Market
TORONTO, Aug. 15, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI)(FRANKFURT: 75M)(OTCQB:MRRCF) (“Maricann” or the “Company) is pleased to announce that the Company has successfully exported dry cannabis flowers to Germany. The recent shipment of dry cannabis flowers from its EU-GMP certified facility in Langton, ON Canada, was successfully exported from Canada and then imported to Germany. The material then underwent further analytical testing and met all specifications and requirements. The Company will now move to export further product to the German medical market.
As one of five companies with EU-GMP certified facilities for cannabis production globally, we are positioned perfectly to capture market share in the European medical market. This step further validates the platform that we have built at Maricann, with EU-GMP certified cannabis flower exports from our facilities in Canada now a reality.
Ben Ward, CEO of Maricann
Maricann Inc., a wholly owned subsidiary of Maricann Group Inc., received an export permit from Health Canada on April 16, 2018 to ship dried cannabis flower to Germany. These results are the culmination of those efforts and represent yet another instance of external validation for the Company and its products.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) and will continue to pursue new opportunities in Europe.